Price: $0.0000
$0.00
%
|
Day's High:
| 0.00
| Week Perf:
|
|
Day's Low: |
$ 0.00 |
30 Day Perf: |
|
Volume (M): |
0 |
52 Wk High: |
$ 0.00 |
Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.00 |
Open: |
$0.00 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
730 |
Employees |
6,012 |
Revenues (TTM) (Millions $) |
16,982 |
Net Income (TTM) (Millions $) |
1,834 |
Cash Flow (TTM) (Millions $) |
7,124 |
Capital Exp. (TTM) (Millions $) |
695 |
Celgene Corp
Celgene Corp is a biopharmaceutical company that focuses on developing innovative therapeutics for the treatment of cancer and other serious medical conditions. The company was founded in 1986 and is headquartered in Summit, New Jersey, USA. It is widely known for its pioneering work in multiple myeloma, a rare type of cancer that affects plasma cells in the bone marrow.
Celgene's mission is to improve the lives of patients and their families by developing and commercializing therapies that target a wide range of diseases, including cancer, inflammatory conditions, and autoimmune disorders. The company's expertise lies in drug discovery, preclinical research, clinical development, and commercialization.
Celgene has a diverse pipeline of products, which includes multiple myeloma, leukemia, lymphoma, solid tumors, and inflammatory conditions such as psoriasis and Crohn's disease. The company's flagship product is Revlimid (lenalidomide), a first-in-class oral therapy for the treatment of multiple myeloma and myelodysplastic syndromes.
In addition to Revlimid, Celgene also markets Pomalyst (pomalidomide) for multiple myeloma and Dexamethasone for inflammatory conditions. The company's portfolio also includes Otezla (apremilast), a first-in-class oral therapy for the treatment of psoriasis and psoriatic arthritis.
Celgene is committed to advancing the science and understanding of diseases through research collaborations and partnerships with academic institutions, industry organizations, and patient advocacy groups. The company has a strong corporate responsibility program, which includes initiatives to support patient access to its drugs, advance employee health and wellness, and promote environmental sustainability.
Overall, Celgene is a biopharmaceutical company that is dedicated to using innovative science to improve the lives of patients affected by serious medical conditions. The company's focus on drug discovery, clinical development, and commercialization has led to the development of groundbreaking therapies, including several first-in-class medicines that have transformed the treatment landscape for cancer and other diseases.
Company Address: 86 Morris Avenue Summit, 7901 NJ
Company Phone Number: 673-9000 Stock Exchange / Ticker: NASDAQ CELG
|
|
Customers Net Income grew by |
CELG's Customers Net Profit Margin grew to |
29.46 % |
3.96 %
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Leap Therapeutics Inc
Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million. Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.
|
Xbiotech Inc
Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects. One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.
|
Acurx Pharmaceuticals Inc
Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average. The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.
|
Soligenix Inc
As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year. In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance. Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.
|
Eterna Therapeutics Inc
In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products. Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.
|
Per Share |
Current |
Earnings (TTM) |
8.12 $ |
Revenues (TTM) |
23.28 $
|
Cash Flow (TTM) |
9.77 $ |
Cash |
14.92 $
|
Book Value |
16.57 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
8.12 $
|
Revenues (TTM) |
23.28 $ |
Cash Flow (TTM) |
9.77 $ |
Cash |
14.92 $
|
Book Value |
16.57 $ |
Dividend (TTM) |
0 $ |
|
|
|
REVLIMID |
|
Segment |
|
|
of total Revenue |
THALOMID |
|
Segment |
|
|
of total Revenue |
ABRAXANE |
|
Segment |
|
|
of total Revenue |
VIDAZA |
|
Segment |
|
|
of total Revenue |
Other |
|
Segment |
|
|
of total Revenue |
Total product sales |
|
Segment |
|
|
of total Revenue |
ISTODAX |
|
Segment |
|
|
of total Revenue |
POMALYST, IMNOVID |
|
Segment |
|
|
of total Revenue |
azacitidine injection |
|
Segment |
|
|
of total Revenue |
|
|
|